Search research articles

Search research articles

Related Experiment Videos

Is cortical bone hip? What determines cortical bone properties?

¹Medicine and Geriatrics, Mount Sinai School of Medicine, New York, USA. bonedocsol@aol.com

|May 1, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition.

Matrix biology : journal of the International Society for Matrix Biology·2018

Same author

Corrigendum to "The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes".

International journal of endocrinology·2017

Same author

Metabolic Bone Disease in the Post-transplant Population: Preventative and Therapeutic Measures.

The Medical clinics of North America·2016

Same author

Secondary osteoporosis: pathophysiology & diagnosis.

Best practice & research. Clinical endocrinology & metabolism·2014

Same author

Questioning the association between bisphosphonates and atypical femoral fractures.

Annals of the New York Academy of Sciences·2014

Same author

The alliance of mesenchymal stem cells, bone, and diabetes.

International journal of endocrinology·2014

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Reducing bone turnover and increasing bone mineral density (BMD) are key to decreasing fracture risk. Osteocyte health and periosteal cells are vital for skeletal integrity and fracture prevention, especially in cortical bone.

Area of Science:

Bone biology
Skeletal integrity
Osteoporosis research

Background:

Increased bone turnover can disrupt bone structure, leading to fractures.
Cortical bone requires reduced turnover and increased bone mineral density (BMD) to lower hip fracture risk.
Cortical porosity and reduced thickness are linked to hip fractures, highlighting the importance of bone strength.

Purpose of the Study:

To explore factors influencing bone strength and deterioration.
To investigate the role of osteocyte viability and apoptosis in bone loss and aging-related fractures.
To evaluate pharmacological agents targeting osteocytes and periosteal cells for fracture reduction.

Main Methods:

Analysis of bone turnover, bone mineral density (BMD), and cortical porosity.

Related Experiment Videos

Assessment of osteocyte viability and apoptosis in relation to loading.

Review of bisphosphonate (alendronate, risedronate, ibandronate), anabolic agent (PTH(1-34)), and RANKL inhibitor (denosumab) effects on bone.

Main Results:

Osteocyte apoptosis is a major factor in age-related bone loss and fracture.
Bisphosphonates like alendronate, risedronate, and ibandronate show benefits in preserving cortical bone, reducing resorption, and increasing BMD.
Anabolic agents and RANKL inhibitors like denosumab also demonstrate positive effects on bone remodeling and BMD.

Conclusions:

Osteocyte and periosteal cell function are critical for maintaining skeletal integrity.
Pharmacological interventions targeting these cells and pathways can reduce bone loss and fracture risk.
Further research into bone strength determinants promises significant advancements in fracture prevention strategies.